AstraZeneca to use American AI platform for cancer trials
Av New York-based Immunai uses so-called single-cell genomics, a technique for understanding the genetic makeup of single cells, and machine learning to improve the development of new therapies. The company has built a digital map of the immune system by mapping the function of each cell type and their interactions with the body and various diseases.
The two companies have previously collaborated on research in inflammatory bowel disease, but are expanding this to also apply to cancer.
The agreement initially means that AstraZeneca will pay $18 million to use Immunai's AI model to potentially reach new insights into the mechanisms of action of immunotherapies, writes Reuters. Among other things, it involves identifying which patients are most likely to respond to different treatments, based on profiles of their immune system and the properties of the drug.
According to Immunai, the collaboration will focus on clinical decision-making, including dose selection and biomarker identification, and Astra Zeneca has the option to expand the length and scope of the collaboration.
Artikeln är en del av vårt tema om News in English.